LIVE WEBINAR: Tuesday, January 24, 2023, 5:00 PM – 6:00 PM Eastern Time (ET)

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Oncology

A Multitumor CME/MOC-Accredited Live Webinar Series

Gynecologic Oncology

Join us on Tuesday, January 24th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Michael J Birrer, MD, PhD
Vice Chancellor, UAMS
Director, Winthrop P Rockefeller Cancer Institute
Director, Cancer Service Line
Professor of Biochemistry and Molecular Biology
Director’s Endowed Chair for the Winthrop P Rockefeller Cancer Institute
University of Arkansas for Medical Sciences
Little Rock, Arkansas

Kathleen N Moore, MD, MS
Associate Director, Clinical Research
Virginia Kerley Cade Chair in Developmental Therapeutics
Director, TSET Phase I Drug Unit
Co-Director, Cancer Therapeutics Program
Stephenson Cancer Center at the University
of Oklahoma HSC
Associate Director, GOG Partners
Board of Directors, GOG Foundation
Oklahoma City, Oklahoma

Neil Love, MD
Research To Practice
Miami, Florida

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Karyopharm Therapeutics, and Mersana Therapeutics Inc.

Tuesday, January 24, 2023
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

  • Module 1: Ovarian Cancer
  • Module 2: Endometrial Cancer
  • Module 3: Cervical Cancer

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gynecologic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Assess available clinical trial data with and approved indications for the use of FDA-endorsed PARP inhibitors for newly diagnosed and recurrent ovarian cancer (OC) in order to optimally incorporate these agents into patient care.
  • Appreciate the biologic rationale for and published clinical research with the use of PARP inhibitors in combination with other systemic therapies, and consider the current and potential clinical and research implications of these findings on OC management.
  • Recognize the rationale for targeting folate receptor alpha and sodium-dependent phosphate transport protein 2b for OC, and consider available and emerging research findings with and the potential role of novel approaches to therapeutically exploit these biomarkers.
  • Review the benefits observed with the use of anti-PD-1/PD-L1 antibodies for advanced microsatellite instability-high or mismatch repair-deficient endometrial cancer (EC), and integrate these agents into the care of appropriate patients.
  • Consider the biologic rationale for and available data with the use of anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC ideal for treatment with this novel approach.
  • Evaluate published efficacy and safety findings with the use of anti-PD-1 antibodies as monotherapy or in combination with chemotherapy for metastatic cervical cancer (CC), and consider the current and future roles of immune checkpoint inhibition in the treatment of this disease.
  • Recognize the incidence of tissue factor expression in patients with CC, and assess the current and future roles of novel agents designed to exploit this therapeutic target.
  • Reflect on investigational agents and strategies currently in testing for OC, EC and CC, and refer eligible patients for clinical trial participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr BirrerAdvisory Board: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Mersana Therapeutics Inc. Dr MooreAdvisory Committee: Aadi Bioscience, Alkermes, Aravive Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Clovis Oncology, Eisai Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, I-Mab Biopharma, ImmunoGen Inc, InxMed, Lilly, Merck, Mereo BioPharma, Mersana Therapeutics Inc, Myriad Genetic Laboratories Inc, Novartis, Onconova Therapeutics Inc, OncXerna Therapeutics Inc, Tarveda Therapeutics, Tesaro, A GSK Company, VBL Therapeutics, Verastem Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Verastem Inc; Contracted Research: GlaxoSmithKline, Lilly, Merck, PTC Therapeutics, Verastem Inc.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Karyopharm Therapeutics, and Mersana Therapeutics Inc.